· Log in

Cortex`s CEO to Present at Rodman & Renshaw`s Eleventh Annual Healthcare Conference

Written by: SFD News on September 3rd, 2009

Cortex`s CEO to Present at Rodman & Renshaw`s Eleventh Annual Healthcare Conference | read this item

Cortex Pharmaceuticals, Inc. (NYSE Amex: COR) President and CEO, Mark A. Varney,
Ph.D., will present at Rodman & Renshaw`s Eleventh Annual Healthcare
Conferencetaking place September 9 – 11, 2009, at the New York Palace Hotel. Dr.
Varney will give the Company presentation on Thursday, September 10 at 3:40 PM
(EDT) in the Garrison Room. Additional information regarding the conference can
be found at http://rodm.com/conferences?id=30.

Dr. Varney will provide an update on Cortex`s partnering activities, the
Company`s financials, and the latest clinical developments, including the
progress of enrollment in Cortex`s clinical trial of CX1739 in patients with
moderate to severe sleep apnea. Chronic sleep apnea can lead to serious
long-term consequences such as cardiovascular disease, stroke and diabetes. In a
prominent article published last month by researchers at Johns Hopkins
University, individuals with severe sleep apnea were 46 percent more likely to
die from any cause, regardless of age, sex, race, weight or smoking. There is
currently no drug treatment for sleep apnea.

The Company has two compounds in clinical development: CX1739, which is targeted
for sleep apnea and ADHD, and intravenous CX717 for treatment of drug-induced
respiratory depression. Recent publications have shown that respiratory
depression can be a very serious side effect when anesthetic agents,
benzodiazepines, and opioid analgesics are given to patients, particularly when
administered in combination. The most public example of such problems was
highlighted in the press with the recent death of Michael Jackson, which was
reportedly associated with the administration of the anesthetic agent, propofol
(Diprivan). Recent studies performed by Dr. John Greer at the University of
Alberta, Canada with Cortex`s AMPAKINE molecules in animal studies demonstrated
that CX717 can prevent propofol-induced respiratory depression. The unique
feature of i.v.CX717 and potentially CX1942, another compound under development
by Cortex, is that they can prevent or reverse such effects and potentially save
patients` lives without impairing the analgesic or sedative effects.

To access a live audio webcast or the subsequent archived recording, log on to
http://www.wsw.com/webcast/rrshq15/cor. Please connect to the website several
minutes prior to the start of the live webcast to ensure adequate time for any
software download that may be necessary. An archive of the replay will be
available for ninety days at http://www.cortexpharm.com.

Cortex Pharmaceuticals, Inc.

Cortex, located in Irvine, California, is a neuroscience company focused on
novel drug therapies for treating psychiatric disorders, neurological diseases
and brain mediated breathing disorders. Cortex is pioneering a class of
proprietary pharmaceuticals called AMPAKINE compounds, which act to increase the
strength of signals at connections between brain cells. The loss of these
connections is thought to be responsible for memory and behavior problems in
Alzheimer`s disease. Many psychiatric diseases, including schizophrenia, occur
as a result of imbalances in the brain`s neurotransmitter system. These
imbalances may be improved by using the AMPAKINE technology. For additional
information regarding Cortex, please visit Cortex Pharmaceuticals` website at

http://www.cortexpharm.com.